^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BGB-A3055

    i
    Associations

    News

    Trials
    Company:
    BeiGene
    Drug class:
    CCR8 inhibitor
    Related drugs:
    Associations

    News

    Trials
    9d
    BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=263, Recruiting, BeiGene | Trial completion date: Feb 2025 --> Mar 2027 | Trial primary completion date: Feb 2025 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    1year
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over1year
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=318, Recruiting, BeiGene | Phase classification: P1a/1b --> P1
    Phase classification • Combination therapy • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over1year
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=318, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • IO biomarker • Metastases
    |
    CCR8 (C-C Motif Chemokine Receptor 8)
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055
    over1year
    A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=318, Not yet recruiting, BeiGene
    New P1 trial • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
    |
    PD-L1 expression • CCR8 expression
    |
    Tevimbra (tislelizumab-jsgr) • BGB-A3055